Gilead HCV combo granted speedy EU assessment
This article was originally published in Scrip
Gilead Sciences' once-daily, fixed dose combination of ledipasvir and sofosbuvir has been granted accelerated assessment by the European Medicines Agency, following the company's Marketing Authorisation Application (MAA) in February. The speeded up process could shorten the review time by about two months. The hepatitis C treatment, if approved, could therefore be available in the EU by the end of 2014.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.